Trials / Unknown
UnknownNCT02453893
Risperidone-controlled,Multicentre Clinical Trial of Iloperidone in Patients With Schizophrenia
Double-blind,Double-simulation,Risperidone-controlled,Multicentre Clinical Trial of Iloperidone in Patients With Schizophrenia
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 288 (estimated)
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This research is a Randomized, double-blind, risperidone-controlled, multicenter clinical study. Chinese subjects with Ischemic Schizophrenia.
Detailed description
Subjects will randomly enter into one of two groups,the period of treatment is 8 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Iloperidone | |
| DRUG | Risperidone |
Timeline
- Start date
- 2013-11-01
- Primary completion
- 2015-06-01
- First posted
- 2015-05-27
- Last updated
- 2015-05-27
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02453893. Inclusion in this directory is not an endorsement.